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Abstract 
BACKGROUND: 
Antiphospholipid syndrome is defined by the combination of thrombotic events and/or obstetric 
morbidity in patients who have tested positive persistently for antiphospholipid antibodies. With 
good treatment, approximately 70% of pregnant women with antiphospholipid syndrome will 
deliver a viable live infant. However, current management does not prevent all maternal, fetal, and 
neonatal complications of antiphospholipidsyndrome. 
OBJECTIVES: 
This observational, retrospective, single-center cohort study aimed to assess pregnancy 
outcomein women with antiphospholipid antibodies who were treated with hydroxychloroquine in 
addition to conventionaltreatment during pregnancy. 
STUDY DESIGN: 
One-hundred seventy pregnancies in 96 women with persistent antiphospholipid antibodies were 
analyzed: (1) 51 pregnancies that occurred in 31 women were treated with hydroxychloroquine for 
at least 6 months before pregnancy, and the therapy continued throughout gestation (group A); (2) 
119 pregnancies that occurred in 65 women with antiphospholipid antibodies that were not treated 
with hydroxychloroquine were included as controls (group B). 
RESULTS: 
Hydroxychloroquine-treatment was associated with a higher rate of live births (67% group A vs 
57% group B; P = .05) and a lower prevalence of antiphospholipid antibodies-
related pregnancy morbidity (47% group A vs 63% B; P = .004). The association 
of hydroxychloroquine with a lower rate of any complication in pregnancywas confirmed after 
multivariate analysis (odds ratio, 2.2; 95% confidence interval, 1.2-136; P = .04). Fetal losses at >10 
weeks of gestation (2% vs 11%; P = .05) and placenta-mediated complications (2% vs 11%; P = 
.05) were less frequent in group A than group B. Pregnancy duration was longer in group A than 
group B (27.6 [6-40] vs 21.5 [6-40] weeks; P = .03). There was a higher rate of spontaneous vaginal 
labor in hydroxychloroquine-treatedwomen compared with group B (37.3% vs 14.3%; P = .01). 
CONCLUSIONS: 
Despite the heterogeneity in the 2 groups in terms of systemic lupus erythematosus prevalence and 
previous pregnancy history, our results support the concept that women with antiphospholipid 
antibodies may benefit from treatment with hydroxychloroquine during pregnancy to 
improve pregnancy outcome. The addition ofhydroxychloroquine to conventional treatment is 
worthy of further assessment in a proper designed randomized controlled trial. 
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Antiphospholipid syndrome (APS) is defined by the combination of thrombotic events and/or 
obstetric morbidity in patients who tested persistently positive for antiphospholipid antibodies 
(aPL). 1 Laboratory tests to identify aPL include solid-phase enzyme-linked immunosorbent assays 
(ELISA) to detect anticardiolipin and anti-β2 glycoprotein 1 antibodies and functional assays for 
lupus anticoagulants. The presence of aPL must be confirmed at least in 2 occasions >12 weeks 
apart.1 
Although initially described in patients with systemic lupus erythematosus (SLE), APS was soon 
recognized to occur also in patients without underlying autoimmune disease (so called primary 
APS).2 Approximately 30% of SLE is positive for aPL3; at 20 years of follow-up observation, there 
is a 50% chance of the development of APS.4 Obstetric morbidity in APS is characterized by early 
complications, such as recurrent abortions before week 10 of gestation, and/or later complications, 
such as fetal death at ≥10 weeks of gestation, and prematurity before 34 weeks of gestation in 
relation with placental insufficiency.1 Placental insufficiency can result in intrauterine growth 
restriction, preeclampsia, eclampsia, placental abruption, and hemolysis, elevated liver enzyme 
levels, and low platelet levels (HELLP) syndrome. 
The prevention of obstetric complications is based on the use of low-dose aspirin and/or 
subcutaneous injections of unfractionated heparin or low–molecular-weight heparin.2, 5 and 6Women 
with APS who have had a previous thrombotic event currently are treated with low-dose aspirin and 
heparin.2 With good treatment, approximately 70% of pregnant women with APS will deliver a 
viable live infant.7 Very recently, Bouvier et al8 confirmed this observation, reporting a live birth 
rate of 69.6% in a cohort of women with a purely obstetric APS who were treated with low-dose 
aspirin and low–molecular-weight heparin. In our unit, overall rates of live birth in women with 
aPL previously have been reported to be as high as 79%.7 
However, current treatment does not prevent all maternal, fetal, and neonatal complications of APS, 
with an overall frequency of failure, despite modern treatment ranges from 20-30%, depending on 
the therapeutic regime, and the history of thrombosis, and/or pregnancy complications. The best 
approach to improve the outcome of these pregnancies is still unknown. 
Our group showed that the addition of first-trimester low-dose prednisolone to conventional 
treatment improved the rate of live births in refractory aPL-related first trimester pregnancy loss. 
After treatment with low-dose prednisolone, nearly two-thirds of pregnancies (61%) resulted in live 
births, of which 8 (57%) were uncomplicated term pregnancies. However, the frequency 
of some complications remained elevated, mainly preterm delivery (21%).9 Other treatments, 
including intravenous immunoglobulin, have failed to confer benefit.10 
Hydroxychloroquine, traditionally an antimalarial drug, has been used widely in the treatment of 
patients with autoimmune conditions, mainly SLE where has been associated with a prevention of 
flares and better survival through its immunomodulatory effects, including antiinflammatory, 
antiaggregant, and immune-regulatory properties.11, 12, 13 and 14 
Original studies of fetal morbidity and death in APS suggested that the pathogenesis was 
thrombotic for second- and third-trimester complications and possibly through trophoblast 
inhibition in first-trimester loss.15 
However, recent animal models and in vitro studies have suggested that the cause of adverse 
pregnancy events in aPL may be caused by inflammatory processes, including increased cytokine 
production, complement deposition, and immune cell activation.16Recently, hydroxychloroquine 
has been shown to reverse the aPL-inhibition of trophoblast interleukin-6 secretion and aPL-
inhibition of cell migration.17 Also, it has been reported that hydroxychloroquine restores 
trophoblast fusion that is affected by aPL.18 These studies suggest that hydroxychloroquine may 
improve pregnancy outcome in women with aPL, especially in those with recurrent pregnancy loss 
refractory to conventional treatment.19 
Several studies have assessed the effect of hydroxychloroquine on pregnancies in women with SLE 
and demonstrated that hydroxychloroquine is safe in pregnancy. In case series published in the 
1980s and 1990s, Parke20 and 21 suggested that hydroxychloroquine was safe to use in pregnant 
patients with SLE. Buchanan et al22 reported that exposure to hydroxychloroquine during pregnancy 
did not have any teratogenic effects. Data regarding 257 pregnancies from the Hopkins cohort 
showed no fetal abnormalities that were attributable directly to hydroxychloroquine; this study also 
reported that the stopping of hydroxychloroquine therapy during or just before pregnancy resulted 
in increased disease activity.23 The European League Against Rheumatism recommendations for the 
management of SLE support the safety and efficacy of hydroxychloroquine during 
pregnancy.24 Very recently, data from a European multicenter retrospective study that included 30 
patients with APS with 35 pregnancies showed a better outcome of pregnancies that were treated by 
the addition of hydroxychloroquine when compared with previous pregnancies under the 
conventional treatment.25 
The purpose of the present cohort study was to assess the outcome of pregnancies in a large cohort 
of women with aPL who were exposed to hydroxychloroquine during pregnancy when compared 
with women with aPL who did not receive hydroxychloroquine therapy. 
Methods 
This was an observational, retrospective, single center cohort study. All the records of women who 
attended the Lupus & Antiphospholipid Pregnancy clinic from January 2008 to July 2014 were 
searched. All the pregnancies in women with persisting aPL were identified. 
aPL positivity was defined according to the current classification criteria and confirmed at least 12 
weeks apart 1 in all the included women before the index pregnancy. Women with equivocal or 
unconfirmed aPL positivity were excluded from our analysis. Our final cohort included 170 
pregnancies, which occurred in 96 women with aPL. 
Anticardiolipin antibodies (isotypes immunoglobulin G and M) were quantified by indirect ELISA 
with the use of AEUSKULISA Cardiolipin-GM reagents (Grifols UK, Cambridge, UK). Anti β2-
glycoprotein I antibodies (isotypes immunoglobulin G and M) were quantified by indirect ELISA 
with the use of QUANTA Lite reagents (INOVA Diagnostics Inc, San Diego, CA). Lupus 
anticoagulant detection that was in compliance with published guidelines26 was determined by 
dilute Russell's viper venom time and dilute activated partial thromboplastin time, accompanied by 
appropriate confirmatory tests. Patients on oral anticoagulation therapy additionally received 
screening with Taipan snake venom time with the use of Diagen Taipan venom (Diagnostic 
Reagents, Thames, UK) with an Ecarin time confirmatory test using Echis carinatus venom 
(Diagnostic Reagents). 
Patients were divided in 2 groups: Group A included aPL patients who received 
hydroxychloroquine treatment during pregnancy. Group B included patients without 
hydroxychloroquine treatment. 
The following baseline data were registered and compared between the 2 groups: frequency of aPL 
only, primary APS, aPL with SLE and APS with SLE, mean disease duration, history of pregnancy 
morbidity and/or thrombosis, conventional risk factors for cardiovascular events 
(hypertension,27 body mass index ≥30 kg/m2, hyperlipemia,28diabetes mellitus,29 smoking>5 
cigarettes/daily), aPL profile, and the presence of other autoantibodies (antinuclear antibodies, anti–
double stranded DNA, anti-extractable nuclear antigens antibodies). 
For each pregnancy, the following data were collected: treatment, pregnancy outcome and 
maternal/fetal/neonatal complications. 
Neonatal outcomes that were recorded included survival, gestational age at delivery, neonatal 
weight, and occurrence of intrauterine growth restriction. 
Pregnancy morbidity was defined according to the current classification criteria for APS. 1 
Therapy other than hydroxychloroquine varied according to the clinical manifestations and can be 
summarized in the following manner: women without previous pregnancy morbidity or thrombosis 
received low-dose aspirin. Low–molecular-weight heparin (LMWH) at thromboprophylactic doses 
was associated only if previous failure of low-dose aspirin alone. Women with previous fetal death 
or previous early delivery because of severe preeclampsia or placental insufficiency received low-
dose aspirin plus LMWH at thromboprophylactic doses. Patients with thrombotic APS who undergo 
long-term anticoagulation were treated with low-dose aspirin and LMWH at therapeutic doses. 
Statistical analysis was performed with SPSS software (version 17; SPSS Inc, Chicago, IL) and 
included logistic regression analysis and χ2 and Fisher exact tests with a generalized link function to 
correct pregnancy outcomes for >1 pregnancy in the same woman. 
A stepwise forward conditional procedure that included biologic relevant and significant risk factors 
that were obtained from the univariate analysis was then used for the logistic regression analysis to 
identify significant independent risk factors. Computed variables included age, aPL profile, 
presence of SLE, history of pregnancy morbidity and/or thrombosis, presence of other 
autoantibodies (antinuclear antibodies, anti–double stranded DNA, anti-extractable nuclear antigens 
antibodies, treatment during pregnancy (low-dose aspirin, LMWH, steroids, and/or 
immunosuppressant use). 
Patients 
Previous obstetric and thrombotic events, concomitant autoimmune conditions, and autoantibodies 
are shown in Table 1. 
Hydroxychloroquine group (group A) 
Between January 2008 and July 2014, 51 pregnancies occurred in 31 women who had been treated 
with hydroxychloroquine for at least 6 months before pregnancy (mean time treatment before 
pregnancy, 41.7 ± 9.2 months) and continued throughout gestation (only 1 patient started 
hydroxychloroquine at the time of a positive pregnancy test). Indications for hydroxychloroquine 
treatment were SLE as defined by the American College of Rheumatology criteria30 (n = 20; 
64.5% of group A). One patient did not meet 4 American College of Rheumatology classification 
criteria for SLE but had arthralgias and was positive for anti-SSA/Ro antibodies (n = 1; 3.2%). In 
patients with primary APS, the indication was lupus-like syndrome (ie, severe fatigue and arthralgia 
without serologic positivity for SLE (n = 10; 32.3%). At study entry, 7 women (22%) were 
primigravid, and 24 were multiparous. Six pregnancies occurred after in vitro fertilization 
treatment. The median age of patients at the time of delivery was 32 years (range, 21–42 years).In 
26 pregnancies, the women received hydroxychloroquine 200 mg twice daily; in 25 pregnancies, 
the women received hydroxychloroquine 200 mg once daily. When low-dose aspirin or heparins 
was excluded, hydroxychloroquine was used in 30 pregnancies as sole immunomodulation 
treatment. Other treatments are reported in Table 2. 
Group not exposed to hydroxychloroquine (group B) 
Between January 2008 and July 2014, 119 pregnancies occurred in 65 women who had not been 
treated with hydroxychloroquine during pregnancy. Five patients with SLE (7.7%) who refused 
hydroxychloroquine treatment (they had concerns about potential side-effects), 45 women (69.2%) 
had primary antiphospholipid syndrome, and 15 patients were aPL positive without previous events 
(23.1%) who did not have clinical indication to receive hydroxychloroquine. 
At study entry, 14 women were primigravid, and 51 women were multiparous. Twenty-two 
pregnancies occurred after in vitro fertilization treatment. The median age at the time of delivery 
was 35.6 years (range, 18–42 years). 
Results 
Treatment with hydroxychloroquine was well tolerated, and no side-effect was reported. No patients 
suspended treatment with hydroxychloroquine during the follow-up period. 
As indicated in Table 1, women who were treated with hydroxychloroquine had a significant higher 
prevalence of SLE (64.5% in group A vs 7.7% in group B; P < .001), which is consistent with 
the higher frequency of antinuclear antibodies and extractable nuclear antigens antibodies that were 
observed in group A (P < .001). Disease duration (either APS and/or SLE) was longer in group A 
when compared with group B (5.3 ± 4.1 vs 2.7 ± 2.4 years). 
Group B had a higher prevalence of primary antiphospholipid syndrome (16.1% in group A vs 
69.2% in group B; P < .001) and of previous pregnancy morbidity (22.6% in group A vs 53.8% in 
group B; P = .004), which failed to reach statistically significance when we analyzed spontaneous 
abortion at <10 week of gestation, fetal loss beyond week 10 of gestation, or placenta-mediated 
complications separately. 
No statistical differences were seen between the 2 groups in age at the start of pregnancy, ethnicity, 
primigravidity, conventional cardiovascular risk factors, and previous thrombotic events. 
Table 2 shows the pregnancy outcome in the 2 groups. Hydroxychloroquine treatment was 
associated with a higher rate of live births (66.7% in group A vs 57.1% in group B; P = .05) and a 
lower prevalence of overall pregnancy morbidity (47.1% in group A vs 63.0% in group B; P = 
.004). 
The beneficial effect of hydroxychloroquine in the reduction of aPL-related complication in 
pregnancy was confirmed after multivariate analysis (odds ratio, 2.2; 95% confidence interval, 1.2–
136; P = .04). 
Previous pregnancy morbidity (odds ratio, 12.1; 95% confidence interval, 1.4–134; P = .03) and 
triple aPL positivity (odds ratio, 2.6; 95% confidence interval, 1.9–22; P = .04) were confirmed as 
independent factors that were related with poor pregnancy outcome after multivariate analysis. 
In details, fetal losses at >10 weeks of gestation were less frequent in group A than group B (2% vs 
10.9%; P = .05). Placenta-mediated complications (preeclampsia, abruption placenta, and 
intrauterine growth restriction were less prevalent in women who were treated with 
hydroxychloroquine than in control subjects (2% vs 10.9%; P = .05); however, when we stratified 
for each manifestation, they did not reach a statistical significance. 
No significant difference was observed when we compared the rate of spontaneous abortions before 
week 10 of gestation. 
We observed a significant higher prevalence of spontaneous vaginal labor in women who were 
treated with hydroxychloroquine compared with group B (37.3% vs 14.3%; P = .01). Overall 
pregnancy duration was longer in group A than group B (27.6 [range, 6-40] vs 21.5 [range, 6-40] 
weeks; P = .03). When calculated for patients who were reaching viability, pregnancy duration was 
confirmed to be longer in group A than group B (39 [range, 34-41] vs 37.5 [range, 31-40]; P = 
.049). 
The rate of preterm live births before week 37 of gestation was lower in group A than group B 
(3.9% vs 13.4%), although it failed to reach a statistical significance. 
No thrombotic event was observed during the follow-up period. 
The included patients with SLE were stably in remission/with low disease activity at the time of 
pregnancy. Only 2 minor flares that consisted in exacerbation of arthralgia were recorded in group 
A; the flares were treated with minimal adjustment of oral steroids dose (up to 7.5 mg/d). When we 
stratified for SLE clinical manifestations, which included lupus nephritis, no further association 
with any pregnancy morbidity was observed. 
Comment 
To the best of our knowledge, this study is the first to provide clinical evidence from a large cohort 
that supports a beneficial effect of hydroxychloroquine on pregnancy outcome in women with aPL. 
In our study, hydroxychloroquine was well tolerated, and no serious side-effects were observed. 
The main serious effects that are associated with hydroxychloroquine exposure are very rare and 
involve cardiac and retinal toxicities.31 Cardiac toxicity remains controversial; in the largest 
prospective study, the rate of heart conduction disorders during the 12-month follow-up period was 
similar to what is expected in the general population.32 With regard to retinal toxicity, a follow-up 
study that included 2043 adult patients showed 0.1% of hydroxychloroquine-related retinopathy that 
was associated with a median duration of hydroxychloroquine treatment of >10 years.12 With 
regard to the fetal outcome in pregnancies that were treated with hydroxychloroquine, several 
studies have shown no significant risk of congenital malformations, retinopathy, or 
ototoxicity.33 and 34 Taken all together, the risk of hydroxychloroquine-related side-effects seems 
negligible when exposure is <12 months, making hydroxychloroquine a suitably low-risk drug to 
trial in pregnancy. Its use during pregnancy is now recommended in the European League Against 
Rheumatism guidelines for SLE management.24 
Previous studies supported the use of aspirin and LMWH as standard treatment for aPL-related 
pregnancy morbidity.6, 8 and 14 However, in a recent observational study, aspirin and LMWH 
treatment failed to reduce the incidence of placenta-mediated adverse pregnancy outcome.8 An 
excess of placenta-mediated complications of 7.8% was observed when we compared women with 
APS with control subjects. These results suggest that current treatments are of limited efficacy in 
the prevention of late pregnancy complication; our data suggest a role for hydroxychloroquine in 
this setting. 
In our cohort, the use of hydroxychloroquine was associated with a higher rate of live births and a 
lower frequency of overall aPL-related pregnancy complication. In detail, the use of 
hydroxychloroquine was associated with both a lower incidence of fetal loss and placenta-mediated 
complications (P = .05). Hydroxychloroquine showed beneficial effect on the overall duration of 
the gestation (P = .034), with a marginally statistical benefit on reduction of the rate of preterm 
births (P = .06). 
In our study, there were no differences in the rate of abortions before week 10 of gestation in the 2 
groups. Previously, no difference in the rate of spontaneous abortion recurrences has been observed 
in women with APS who were treated with LMWH and low-dose aspirin when compared with 
control subjects.8 This finding may reflect different underlying mechanisms for early and late 
pregnancy complications. Because of its preliminary nature, this study was not powered to analyze 
this aspect specifically. 
Recent in vitro studies have shown that the immunomodulatory properties of hydroxychloroquine 
may confer beneficial effects on pregnancy outcome in patients with aPL, potentially the ability of 
aPLs to target both the fetal side (invading trophoblast)18 and 35directly and the maternal side 
(decidua and endometrial endothelial cells)36 of the human placenta and to induce a negative effect 
on placentation. 
We acknowledge some major limitations in this study. First, this was a retrospective study, and 
these findings should be confirmed in a prospective fashion. Second, the prevalence of SLE is 
different between group A and B. Furthermore, we observed a higher frequency of previous 
pregnancy morbidity in the patients who were not treated with hydroxychloroquine, which 
potentially reflects the higher percentage of primary antiphospholipid syndrome in group B 
compared with Group A. We are a tertiary referral center for APS, and we treat women with some 
of the worst obstetric histories. We acknowledge that this might represent a bias when data are 
analyzed and that caution should be applied in interpreting our preliminary observations. However, 
the association of a better pregnancy outcome with hydroxychloroquine treatment was confirmed 
after multivariate analysis, which supports the strength of our findings. Third, in this study we could 
not assess the effect of other therapies (including steroids and azathioprine) rather than 
hydroxychloroquine use because treatment was not controlled, but varied according to the clinical 
manifestations. 
In conclusion, the use of hydroxychloroquine during pregnancy seems to be safe and to have a 
beneficial impact on pregnancy outcome in women with aPL when associated with the conventional 
treatment. 
We are currently planning a prospective randomized controlled trial to confirm or refute these 
observations (HYdroxychoroquine vs placebo during Pregnancy in women with AnTIphospholipid 
Antibodies [HYPATIA trial]). 
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Table 1. 
Clinical characteristics of pregnant women with antiphospholipid antibodies who were treated with or without hydroxychloroquine 
Variable Hydroxychloroquine % Without 
hydroxychloroquine 
% Significance 
Patient, n 31  65   
Pregnancies, n 51  119   
Pregnancies per woman, n (range) 1.65 (1-5)  1.83 (1-7)   
Ethnicity, n (%)      
White 17 (54.8)  39 (60)   
Black 6 (19.4)  10 (15.4)   
Other 8 (25.8)  16 (24.6)   
Mean age, y ± SD (range) 32.5 ± 4.6 (21-42)  35.6 ± 5.2 (18-42)  NS 
Antiphospholipid antibodies only, n 6 19.4 15 23.1 NS 
Primary antiphospholipid syndrome, n 5 16.1 45 69.2 P <.001 
Systemic lupus erythematosus + antiphospholipid antibodies, n 11 35.5 0 0.0 P <.001 
Systemic lupus erythematosus and antiphospholipid syndrome, n 9 29.0 5 7.7 P =.006 
Mean disease duration, y ± SD 5.3 ± 4.1 — 2.7 ± 2.4 — P = .042 
Previous thrombosis, n 10 32.3 19 29.2 NS 
Venous 5 16.1 13 20.0 NS 
Arterial 5 16.1 7 10.8 NS 
Previous pregnancy morbidity, n      
Any 7 22.6 35 53.8 P = .004 
Spontaneous abortions before week 10 4 12.9 18 27.7 NS 
Fetal Loss beyond week 10 0 0.0 4 6.2 NS 
Placenta-mediated complicationa 3 9.7 11 16.9 NS 
Antinuclear antibodies, n 23 74.2 13 20.0 P < .001 
Anti-extractable nuclear antigens antibodies (anti-Ro/anti– lupus 
anticoagulant), n 
15 48.4 6 9.2 P < .001 
Lupus anticoagulant positivity, n 21 67.7 49 75.4 NS 
Anticardiolipin antibodies positivity, n 14 45.2 35 53.8 NS 
Immunoglobulin G/immunoglobulin M (GPL/MPL)      
Mean ± SDb 68.8 ± 22.1/49.2 ± 8.7  61.3 ± 20.7/47.9 ± 9.1  NS 
Median (range)b 72.6 (41-110)/48.9 (40-  69.7 (40-107)/49.1 (40-77)  NS 
Variable Hydroxychloroquine % Without 
hydroxychloroquine 
% Significance 
75) 
Antibeta2-glycoprotein I positivity (GPL/MPL), n 6 19.4 6 9.2 NS 
Immunoglobulin G/immunoglobulin M      
Mean ± SDb 35.3 ± 20.7/30.8 ± 18.6  36.3 ± 18.7/29.4 ± 12.6  NS 
Median (range)b 22 (15-75)/20 (14-70)  20.5 (15-65)/18 (14-59)  NS 
Cardiovascular risk factors, n      
Smoking >5 cigarettes 3 9.7 1 1.5 NS 
Diabetes mellitus26 0 0.0 4 (Gestational) 6.2 NS 
Hyperlipidemia25 0 0.0 0 0.0 NS 
Hypertension24 2 6.5 10 15.4 NS 
GPL, IgG antiphospholipid units/mL; MPL, IgM antiphospholipid units/mL; NS, not significant. 
a Placenta-mediated complication; preeclampsia, abruption placentae, intrauterine growth restriction 
b Evaluated in positive tests only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. 
Pregnancy outcomes of pregnant women with antiphospholipid antibodies who were treated with or without hydroxychloroquine 
Variable Hydroxychloroquine % Without hydroxychloroquine % Significance 
Pregnancies, n 51  119   
Live births, n 34 66.7 60 57.1 P = .05 
Antiphospholipid antibody–related pregnancy morbidity, n 20 47.1 75 63.0 P = .004 
Preterm live births <37 weeks, n 2 3.9 16 13.4 P = .06 
Spontaneous abortions before the week 10, n 16 31.4 46 38.7 NS 
Fetal loss beyond the week 10, n 1 2.0 13 10.9 P = .05 
Placenta mediated complication, n 1 2.0 13 10.9 P = .05 
 Preeclampsia 1 2.0 8 6.7 NS 
 Abruption placentae 0 0 3 2.5 NS 
 Intrauterine growth restriction 0 0 2 1.7 NS 
Mode of delivery, n      
 Vaginal      
 Spontaneous 19 37.3 17 14.3 P = .011 
 Induced 3 5.9 9 7.6 NS 
 Cesarean 10 19.6 23 19.3 NS 
Median gestation duration, wk (range) 27.6 (6-40) — 21.51 (6-40)  P = .034 
Birthweight, kg (range)a 3 (1.3-5) — 2.3 (1.4-4.1) — P = .04 
Prednisolone, 21 41.2 13 11.0 P < .001 
 mean mg/d 5  5  NS 
Azathioprine, n 15 29.4 5 4.2 P < .001 
 Mean mg/d 100  150  NS 
Low-dose aspirin, n 100 100 100 100 NS 
Low–molecular-weight heparin, n 37 72.5 94 79.0 NS 
NS, not significant. 
a For viable live infants. 
 
